Prophylactic antibiotic therapy is associated with an increased prevalenceof Aspergillus colonization in adult cystic fibrosis patients

Citation
J. Bargon et al., Prophylactic antibiotic therapy is associated with an increased prevalenceof Aspergillus colonization in adult cystic fibrosis patients, RESP MED, 93(11), 1999, pp. 835-838
Citations number
18
Categorie Soggetti
Cardiovascular & Respiratory Systems","da verificare
Journal title
RESPIRATORY MEDICINE
ISSN journal
09546111 → ACNP
Volume
93
Issue
11
Year of publication
1999
Pages
835 - 838
Database
ISI
SICI code
0954-6111(199911)93:11<835:PATIAW>2.0.ZU;2-H
Abstract
Aspergillus colonization is a common phenomenon in adult cystic fibrosis (C F) patients. The clinical significance of Aspergillus for the pathogenesis of CF lung disease remains unclear and factors predisposing to such coloniz ation are still completely unknown. We investigated the prevalence of Aspergillus colonization in 104 adult CF patients who attended our outpatient clinic in 1997. With respect to demogr aphic and clinical data, and antibiotic therapy received, we further examin ed which factors were associated with Aspergillus colonization in these pat ients. Repeated investigations of CF sputum samples revealed Aspergillus species i n 43/104 (41.3%; 95% confidence interval 30.2-52.5%) of the patients. We fo und no significant relationship between Aspergillus colonization and age (P > 0.4), gender (P = 0.4), colonization with pseudomonas species (P > 0.6), lower lung function values (P > 0.9), or worse chest radiography (P > 0.1) . Surprisingly, the prevalence of Aspergillus colonization was higher in CF patients receiving prophylactic antibiotic therapy (oral antibiotics: P = 0.05; inhalative antibiotics: P = 0.035; both antibiotics: P = 0.048). Prophylactic antibiotics are widely used to eradicate or decrease chronic b ronchopulmonary infection in CF. Our results indicate that long-term antibi otic therapy may predispose CF patients to Aspergillus colonization. (C) 19 99 HARCOURT PUBLISHERS LTD.